Abstract: The present invention relates to a sandwich immunoassay and kits for detecting in a biological sample cross-linked CTX-III, and its use in evaluating the efficacy of drugs targeting lysyl oxidases (LOXs). Cross-linked CTX-III can be used as a biomarker in diseases associated with fibrosis, including liver fibrosis, chronic intestinal disease, eosinophilic esophagitis and cancer.

Abstract: The present invention relates to methods of immunoassay for detecting HNE-generated fragments of the ?1 chain of type III collagen in a patient sample, and the use thereof for detecting and/or monitoring inflammatory bowel disease (IBD) or a particular level of severity thereof in a patient. The present invention also relates to monoclonal antibodies and assay kits for use in said methods of immunoassay.

Abstract: Disclosed herein are methods of immunoassay for detecting a fibroblast activation protein (FAP) generated fragment of type III collagen in a patient sample, and the use thereof for detecting and/or monitoring cancer or arthritis or a particular level of severity thereof in a patient. Also described are monoclonal antibodies and assay kits for use in said methods of immunoassay.

Abstract: Described herein is a method of immunoassay (the “PRO-C17 assay”) for measuring the levels of type XVII collagen ectodomain present in a patient sample, which method of immunoassay can be used for detecting and/or monitoring cancer and/or assessing the severity thereof in a patient. Also described are monoclonal antibodies and assay kits suitable for use in carrying out said methods.

Abstract: Disclosed herein are methods of immunoassay for detecting HNE-generated fragments of club cell secretory protein 16 (CC16) in a patient sample, which methods can be used for detecting and/or monitoring chronic obstructive pulmonary disease (COPD) or idiopathic pulmonary fibrosis (IPF) or a particular level of severity thereof in a patient. Also disclosed are monoclonal antibodies and assay kits for use in said methods of immunoassay.

Abstract: Disclosed herein are methods of immunoassay for detecting and/or monitoring a skin disease in a patient and/or determining the severity of a skin disease in a patient. The methods detect and quantify the levels of a biomarker that has an N-terminus sequence of collagen type VI alpha-6, in a blood-based sample, such as whole blood, plasma or serum, from the patient. Also disclosed are antibodies suitable for use in the methods and immunoassay kits suitable for carrying out the methods.

Abstract: Disclosed herein are methods of immunoassay for detecting and/or monitoring a cancer in a patient by measuring the levels of the N-terminus amino acid sequence TAALGDIMGH (SEQ ID NO: 1) (“PRO-C5”) of the cleaved C-terminal propeptide of the ?2 chain of type V collagen in a patient sample.

Abstract: The present invention relates to an antibody, wherein the antibody is specifically reactive with short isoform collagen type XVIII, but does not react with intermediate isoform collagen type XVIII or with long isoform collagen type XVIII. The invention also relates to the use of the antibody in a method of immunoassay for detecting or quantitating short isoform collagen type XVIII, where the method may be used to evaluate haemophilic disease.

Abstract: Disclosed herein are methods of immunoassay for detecting HNE-generated fragments of the ?3 chain or ?4 chain of type IV collagen in a patient sample, and the use thereof for detecting and/or monitoring inflammatory bowel disease (IBD) or a particular level of severity thereof in a patient. Also disclosed are monoclonal antibodies and assay kits for use in the methods of immunoassay.

Abstract: The present invention relates to methods of immunoassay suitable for detecting and/or monitoring a cancer in a patient, immunoassay kits suitable for carrying out the methods and antibodies suitable for use in the methods and kits.

Abstract: Described herein are immunoassay methods for detecting and/or monitoring a cancer in a patient. In the method a biofluid sample from a patient is contacted with a monoclonal antibody that specifically binds to a C-terminal epitope of type XXVIII collagen, and the amount of binding between the monoclonal antibody and peptides in the sample is detected and determined.

Abstract: The present invention relates to an assay for detecting secreted proteome acidic and rich in cysteine (SPARC), and more specifically to its use in evaluating lung cancer.

Abstract: An assay measuring protease mediated degradation of type IV collagen and its biomarker potential for identifying cancer patients with a T-cell permissive tumor microenvironment is described.

Abstract: The present invention relates to monoclonal antibodies that target collagen type XIX and to the sequences of the complementarity-determining regions distinguishing the monoclonal antibodies. Also, the present invention relates to immunoassays and to kits employing the antibodies. The assays of the invention are used in the diagnosis and monitoring of cancer.

Abstract: The present invention provides monoclonal antibodies that target collagen type XXIII, and to immunoassays and kits employing the antibodies for detecting and quantifying the epitope. The invention also provides a method for identifying and monitoring subjects with inflammatory bowel disease.

Abstract: Provided herein is an antibody specifically reactive with an N-terminus neo-epitope of collagen type X alpha 1 in the amino acid sequence H2N-GIATKGLNGP, and its use in an immunoassay for evaluating a disease associated with collagen type X alpha 1, such as osteoarthritis.

Abstract: Disclosed herein are methods of immunoassay for detecting, in a patient sample, the third laminin-like globular domain (LG3) fragment cleaved and released from endorepellin/perlecan by bone morphogenetic protein-1 (BMP-1). Also disclosed are monoclonal antibodies and immunoassay kits for use in these methods of immunoassay, as well as the use of these methods of immunoassay for detecting and/or monitoring fibrotic kidney diseases, such as Lupus Nephritis (LN) or IgA nephropathy (IgAN), or particular levels of severity thereof.

Abstract: Provided herein are monoclonal antibodies, assay kits and immunoassay methods for quantifying anastellin fragments with a N-terminus amino acid sequence PIQWNAPQPS (SEQ ID NO: 1) in a patient biofluid sample. Also provided are methods for detecting and/or for monitoring fibrotic diseases such as idiopathic pulmonary fibrosis (IPF) using the monoclonal antibodies.

Abstract: Described herein are monoclonal antibodies, assay kits and immumoassay methods for quantifying anastellin fragments with a N-terminus amino acid sequence PIQWNAPQPS (SEQ ID NO: 1) in a patient biofluid sample, and uses thereof for detecting and/or monitoring fibrotic diseases such as idiopathic pulmonary fibrosis (IPF).

Abstract: Described herein are methods of immunoassay for detecting and/or monitoring cancer in a patient. A sample from the patient is contacted with denatured type III collagen. The amount of binding between the denatured type III collagen and antibodies in the sample that specifically recognise and bind to denatured type III collagen is then detected and determined, and the amount of binding is correlated with values associated with normal healthy subjects, and/or with values associated with known disease severity, and/or with values obtained from the patient at a previous time point, and/or with a predetermined cut-off value.